Pharmacogenetic tests open the door to a new era in personalized medicine by analyzing the genetic differences that affect drug metabolism and efficacy. By predicting how patients will respond to medication, these tests enable individualized treatment approaches that reduce side effects and improve outcomes.
Our laboratory performs comprehensive pharmacogenetic analyses of the CYP2C9, CYP2C19, CYP2D6 and 5-HTT genes needed to optimize the use of warfarin, clopidogrel and various antipsychotic drugs. In oncology, detection of HER2, ALK-EML4, ROS1, PD-L1&2, EGFR, KRAS, NRAS, BRAF, C-KIT and PDGFRA mutations has become standard practice before targeted therapies are administered.